Acumen Research and Consulting estimates that the global antihypertensive drugs market is anticipated to reach market size of around US$ 45,000 Mn by 2027 and is anticipated to grow at a CAGR of around 5% in terms of revenue during the forecast period 2020 – 2027.
Antihypertensive drugs are employed for the treatment of patients suffering from hypertension. Hypertension is a medical condition, which involves rise in blood pressure in the arteries. Furthermore, the patient suffering from hypertension is highly susceptible to other complications, which include heart failure and aneurysm. Therefore, early diagnosis and treatment with the use of antihypertensive medications are important to treat this medical condition. The demand contains beta blockers, calcium channel antagonists and vasodilatators for some of the anti-hypertensive medications. Such medications are prescribed by the doctor and are used in drug shops and pharmacies in hospitals.
The global antihypertensive market growth is powered by an increase in the prevalence of hypertension across the globe. In addition, increased awareness of hypertension-related risks is another significant factor that fuels market growth. In fact, rising geriatric and sedentary lifestyles play a crucial role in the global market. But the latest expiry of the patent restricts the anti-hypertensive market from growing. In comparison, research on antihypertensive drugs in developing markets is projected to grow in the period of forecasting to provide productive opportunities.
Diuretics are Expected to Hold a Significant Market Share in the Therapeutic Class
The main therapy for hypertension in most cases is thiazide diuretics. The thiazide diuretic most commonly used in the U.S. is hydrochlorothiazide. The Joint National Hypertension Committee recommended that the thiazide-type diuretic drug, both used in isolation and along with other antihypertensive medications, such as calcium channel blockers, be one of the approved therapeutic treatment for hypertension. Moreover, more than one third of adults suffering from hypertension reported taking diuretic drugs.
The market research study on “Antihypertensive Drugs Market (By Therapeutic Class: Calcium Channel Blockers, Beta-adrenergic Blockers, Renin Inhibitors, ACE Inhibitors, Vasodilators, Diuretics, ARBs, Others; By Type: Primary Hypertension, Secondary Hypertension; By Distribution Channel: E-commerce Websites & Online Drug Stores, Retail Pharmacy, Hospital Pharmacy, Others) - Global Industry, Analysis, Market Size, Opportunities and Forecast, 2020 - 2027” offers detailed insights on the global antihypertensive drugs market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report also provides competitive landscape to understand the current stance of particular player. The report provides insights on global antihypertensive drugs market are drug class, type, distribution channel and major geographic regions. The antihypertensive drugs market analysis is provided for major regional markets including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. For each region, the market size for different segments has been covered under the scope of report.
North America dominated the global antihypertensive drugs market due to the high prevalence of hypertension leading to renal and cardiovascular disorders in this region. Non-profit and public awareness-raising organizations are primarily creating opportunities to generate revenue in North America. According to the U.S. Heart Association in 2018, more men, almost half of Americans (46%), had hypertension from 32% under the previous description in the updated guidance. The prevalence of coronary disorders, inappropriate food habits, increased obesity for children as well as for adults, and high prevalence of hypertension leading to death or injury is expected to take Europe second position. Due to the rising levels of cardiovascular disease, policy initiatives for the health sector and a growing population pool, the Asia-Pacific region will witness high growth in the anti-hypertensive drug market.
Major players included in this report Johnson and Johnson Ltd., Merck KGaA, Boehringer Ingelheim GmbH, Bayer AG, AstraZeneca plc, Pfizer, Inc., Takeda Pharmaceutical Co, Ltd.., Sanofi S.A., Daiichi Sankyo Company, Novartis International AG, and others. The reports include important trends as conventional and inorganic growth approaches in the market for anti-hypertensive drugs. Specific businesses depend on strategic growth approaches including product launches, drug approvals and other ones, like patents and events. Acquisitions and partnership & cooperation were inorganic development techniques that were illustrated on the market. Such activities opened the door to the growth of industry players' business and customer base. Business participants in the antihypertensive medicines market continue to see promising opportunities for potential development as demand for antihypertensive medicines on the global market grows.
The global antihypertensive drugs market is segmented as below:
Antihypertensive Drugs Market By Therapeutic Class
Antihypertensive Drugs Market By Type
Antihypertensive Drugs Market By Distribution Channel
Antihypertensive Drugs Market By Geography
Middle East & Africa
Antihypertensive drugs are employed for the treatment of patients suffering from hypertension.
An increase in the occurrence of hypertension across the globe is the major drivers for the growth of the antihypertensive drugs market.
Side effects associated with the drugs are a major factor expected to restraint the growth of the market.
Acumen Research and Consulting says that the antihypertensive drugs market value is anticipated to be worth around US$ 45,000 Mn in 2027.
The antihypertensive drugs market is anticipated to grow around 5% CAGR amid the forecast period 2020-2027
Diuretics therapeutic class segment are expected to hold a significant market share in the antihypertensive drugs market?
Due to the rising levels of cardiovascular disease, policy initiatives for the health sector and a growing population pool, the Asia-Pacific region will witness high growth in the anti-hypertensive drug market.